enGene prices $130M public offering of common shares and pre-funded warrants

enGene Therapeutics Inc.

Pricing of 12,558,823 common shares at $8.50/share and pre-funded warrants for 2,735,295 shares at $8.4999 each.
Gross proceeds expected ~$130M before underwriting discounts and expenses.
Underwriters granted 30-day option to purchase up to 2,294,117 additional common shares.
Offering expected to close on or about November 14, 2025.
Proceeds to advance clinical-stage genetic medicines pipeline, including lead NMIBC candidate detalimogene.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.